C07K 16/3076
Against structure-related tumour-associated moieties
Official title: {against structure-related tumour-associated moieties}
C07K16/3076 (Against structure-related tumour-associated moieties) appears on 772 US grants and 1,426 published applications in this corpus.
Search patents in C07K- Granted patents
- 772
- Published applications
- 1,426
- Assignees
- 540
- Inventors
- 2,205
- Latest grant
- 15 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 3 | 0 |
| 1999 | 5 | 0 |
| 2000 | 1 | 0 |
| 2001 | 0 | 0 |
| 2002 | 4 | 5 |
| 2003 | 8 | 14 |
| 2004 | 0 | 21 |
| 2005 | 5 | 33 |
| 2006 | 6 | 24 |
| 2007 | 8 | 36 |
| 2008 | 14 | 27 |
| 2009 | 13 | 36 |
| 2010 | 39 | 53 |
| 2011 | 17 | 34 |
| 2012 | 35 | 38 |
| 2013 | 35 | 41 |
| 2014 | 35 | 58 |
| 2015 | 45 | 70 |
| 2016 | 56 | 71 |
| 2017 | 38 | 81 |
| 2018 | 35 | 75 |
| 2019 | 45 | 72 |
| 2020 | 42 | 92 |
| 2021 | 53 | 100 |
| 2022 | 44 | 89 |
| 2023 | 48 | 99 |
| 2024 | 50 | 95 |
| 2025 | 49 | 92 |
| 2026 | 38 | 70 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
Recent patents
- Anti-MUC1-C antibodies and CAR-T structures15 Sep 2026US 12,735,503 B2TeneoBio, Inc.
- Compositions and methods for inhibiting T cell exhaustion8 Sep 2026US 12,729,245 B2The Board of Trustees of the Leland Stanford Junior University
- Nectin-4 antibodies and uses thereof1 Sep 2026US 12,723,100 B2Cspc Megalith Biopharmaceutical Co., Ltd.
- Methods of treating paraproteinemic neuropathy with anti-C2 antibodies18 Aug 2026US 12,708,664 B2argenx BV
- Presenting cell and use thereof in cell therapy11 Aug 2026US 12,702,708 B2Innovative Cellular Therapeutics Holdings, Ltd.
- Method for the production of bi-functional cells to treat neoplasia1 Oct 2026US 2026/0297162 A1Eir Biotherapies Srl
- Antibodies and uses thereof1 Oct 2026US 2026/0297188 A1LTZ Therapeutics Inc.
- SIRPalpha Knockout iPSC-derived and CAR-comprising Macrophages with Enhanced Anti-tumor Activity24 Sep 2026US 2026/0284104 A1Wisconsin Alumni Research Foundation
- Bispecific Anti-MUC16 x Anti-CD28 Antibodies and Uses Thereof24 Sep 2026US 2026/0285982 A1Regeneron Pharmaceuticals, Inc.
- Improved glycan-dependent immunotherapeutic bi-specific fusion proteins and chimeric antigen receptors24 Sep 2026US 2026/0286005 A1The Regents of the University of California
Most cited
By later US patents
- Production of anti-self antibodies from antibody segment repertoires and displayed on phage541US 5,885,793 ACambridge Antibody Technology Limited · 1999
- Cells producing antibody compositions with increased antibody dependent cytotoxic activity247US 6,946,292 B2Kyowa Hakko Kogyo Co., Ltd. · 2005
- Production of anti-self bodies from antibody segment repertories and displayed on phage229US 6,582,915 B1Cambridge Antibody Technology Limited · 2003
- Production of anti-self antibodies from antibody segment repertoires and displayed on phage228US 6,593,081 B1Cambridge Antibody Technology Limited · 2003
- Production of anti-self antibodies from antibody segment repertoires and displayed on phage216US 6,521,404 B1Cambridge Antibody Technology Limited · 2003